Open AccessRandomized Controlled Crossover Trials of the Pharmacokinetics of PRC-063, a Novel Multilayer Extended-Release Formulation of Methylphenidate, in Healthy Adults
Author(s) -
Martin A. Katzman,
Greg Mattingly,
Larry J Klassen,
Marc Cataldo,
Graeme Donnelly
Publication year - 2020
Publication title -
journal of clinical psychopharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.786
H-Index - 121
eISSN - 1533-712X
pISSN - 0271-0749
DOI - 10.1097/jcp.0000000000001277
Subject(s) - crossover study , randomized controlled trial , pharmacokinetics , methylphenidate , crossover , medicine , pharmacology , computer science , alternative medicine , psychiatry , artificial intelligence , attention deficit hyperactivity disorder , pathology , placebo
PRC-063 is a once-daily, extended-release oral formulation of methylphenidate hydrochloride developed to provide early and prolonged symptom improvement in patients with attention-deficit/hyperactivity disorder.